261 related articles for article (PubMed ID: 33178014)
1. The Role of Photoactivated and Non-Photoactivated Verteporfin on Tumor.
Wei C; Li X
Front Pharmacol; 2020; 11():557429. PubMed ID: 33178014
[TBL] [Abstract][Full Text] [Related]
2. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.
Brodowska K; Al-Moujahed A; Marmalidou A; Meyer Zu Horste M; Cichy J; Miller JW; Gragoudas E; Vavvas DG
Exp Eye Res; 2014 Jul; 124():67-73. PubMed ID: 24837142
[TBL] [Abstract][Full Text] [Related]
3. Non-Photoinduced Biological Properties of Verteporfin.
Gibault F; Corvaisier M; Bailly F; Huet G; Melnyk P; Cotelle P
Curr Med Chem; 2016; 23(11):1171-84. PubMed ID: 26980565
[TBL] [Abstract][Full Text] [Related]
4. Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells.
Zhou W; Lim A; Elmadbouh OHM; Edderkaoui M; Osipov A; Mathison AJ; Urrutia R; Liu T; Wang Q; Pandol SJ
Free Radic Biol Med; 2024 Feb; 212():493-504. PubMed ID: 38184120
[TBL] [Abstract][Full Text] [Related]
5. Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer.
Feng J; Gou J; Jia J; Yi T; Cui T; Li Z
Onco Targets Ther; 2016; 9():5371-81. PubMed ID: 27621651
[TBL] [Abstract][Full Text] [Related]
6. Determination of the migration effect and molecular docking of verteporfin in different subtypes of breast cancer cells.
Wei C; Li X
Mol Med Rep; 2020 Nov; 22(5):3955-3961. PubMed ID: 32901856
[TBL] [Abstract][Full Text] [Related]
7. Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation.
Wei C; Li X
BMC Cancer; 2020 Oct; 20(1):1042. PubMed ID: 33121449
[TBL] [Abstract][Full Text] [Related]
8. Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm.
Wang C; Zhu X; Feng W; Yu Y; Jeong K; Guo W; Lu Y; Mills GB
Am J Cancer Res; 2016; 6(1):27-37. PubMed ID: 27073720
[TBL] [Abstract][Full Text] [Related]
9. Verteporfin-photodynamic therapy is effective on gastric cancer cells.
Mae Y; Kanda T; Sugihara T; Takata T; Kinoshita H; Sakaguchi T; Hasegawa T; Tarumoto R; Edano M; Kurumi H; Ikebuchi Y; Kawaguchi K; Isomoto H
Mol Clin Oncol; 2020 Sep; 13(3):10. PubMed ID: 32754324
[TBL] [Abstract][Full Text] [Related]
10. The Efficiency of Verteporfin as a Therapeutic Option in Pre-Clinical Models of Melanoma.
Lui JW; Xiao S; Ogomori K; Hammarstedt JE; Little EC; Lang D
J Cancer; 2019; 10(1):1-10. PubMed ID: 30662519
[TBL] [Abstract][Full Text] [Related]
11. Core-matched nanoassemblies for targeted co-delivery of chemotherapy and photosensitizer to treat drug-resistant cancer.
Jiang D; Xu M; Pei Y; Huang Y; Chen Y; Ma F; Lu H; Chen J
Acta Biomater; 2019 Apr; 88():406-421. PubMed ID: 30763634
[TBL] [Abstract][Full Text] [Related]
12. The Photosensitising Clinical Agent Verteporfin Is an Inhibitor of SPAK and OSR1 Kinases.
AlAmri MA; Kadri H; Alderwick LJ; Jeeves M; Mehellou Y
Chembiochem; 2018 Oct; 19(19):2072-2080. PubMed ID: 29999233
[TBL] [Abstract][Full Text] [Related]
13. Verteporfin-induced formation of protein cross-linked oligomers and high molecular weight complexes is mediated by light and leads to cell toxicity.
Konstantinou EK; Notomi S; Kosmidou C; Brodowska K; Al-Moujahed A; Nicolaou F; Tsoka P; Gragoudas E; Miller JW; Young LH; Vavvas DG
Sci Rep; 2017 Apr; 7():46581. PubMed ID: 28429726
[TBL] [Abstract][Full Text] [Related]
14. Photodynamic therapy with verteporfin accelerates apoptotic bleb formation in human ameloblastoma.
Yamashita J; Kimoto A; Teraoka S; Hiraoka Y; Takeda D; Kakei Y; Shigeoka M; Hasegawa T; Akashi M
Oral Dis; 2023 Oct; ():. PubMed ID: 37890051
[TBL] [Abstract][Full Text] [Related]
15. Hippo/YAP pathway for targeted therapy.
Felley-Bosco E; Stahel R
Transl Lung Cancer Res; 2014 Apr; 3(2):75-83. PubMed ID: 25806284
[TBL] [Abstract][Full Text] [Related]
16. Verteporfin Inhibits Cell Proliferation and Induces Apoptosis in Human Leukemia NB4 Cells without Light Activation.
Chen M; Zhong L; Yao SF; Zhao Y; Liu L; Li LW; Xu T; Gan LG; Xiao CL; Shan ZL; Liu BZ
Int J Med Sci; 2017; 14(10):1031-1039. PubMed ID: 28924376
[No Abstract] [Full Text] [Related]
17. Hippo-YAP1 Is a Prognosis Marker and Potentially Targetable Pathway in Advanced Gallbladder Cancer.
García P; Rosa L; Vargas S; Weber H; Espinoza JA; Suárez F; Romero-Calvo I; Elgueta N; Rivera V; Nervi B; Obreque J; Leal P; Viñuela E; Aguayo G; Muñiz S; Sagredo A; Roa JC; Bizama C
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218280
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy.
Juan WC; Hong W
Genes (Basel); 2016 Aug; 7(9):. PubMed ID: 27589805
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors.
Guillemette S; Rico C; Godin P; Boerboom D; Paquet M
J Mammary Gland Biol Neoplasia; 2017 Sep; 22(3):203-214. PubMed ID: 28822004
[TBL] [Abstract][Full Text] [Related]
20. Verteporfin enhances the sensitivity of LOVO/TAX cells to taxol via YAP inhibition.
Shi G; Wang H; Han H; Gan J; Wang H
Exp Ther Med; 2018 Sep; 16(3):2751-2755. PubMed ID: 30210616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
